- Home
- RARE vs AGO Comparison
RARE vs AGO Comparison
Compare RARE & AGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- AGO
- Stock Information
- Founded
- RARE 2010
- AGO 2003
- Country
- RARE United States
- AGO Bermuda
- Employees
- RARE N/A
- AGO N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- AGO Property-Casualty Insurers
- Sector
- RARE Health Care
- AGO Finance
- Exchange
- RARE Nasdaq
- AGO Nasdaq
- Market Cap
- RARE 5.2B
- AGO 4.5B
- IPO Year
- RARE 2014
- AGO 2004
- Fundamental
- Price
- RARE $40.89
- AGO $92.31
- Analyst Decision
- RARE Strong Buy
- AGO Buy
- Analyst Count
- RARE 15
- AGO 3
- Target Price
- RARE $92.00
- AGO $103.33
- AVG Volume (30 Days)
- RARE 1.0M
- AGO 238.7K
- Earning Date
- RARE 02-13-2025
- AGO 02-25-2025
- Dividend Yield
- RARE N/A
- AGO 1.01%
- EPS Growth
- RARE N/A
- AGO 73.00
- EPS
- RARE N/A
- AGO 13.02
- Revenue
- RARE $522,745,000.00
- AGO $867,000,000.00
- Revenue This Year
- RARE $26.70
- AGO N/A
- Revenue Next Year
- RARE $19.02
- AGO N/A
- P/E Ratio
- RARE N/A
- AGO $7.04
- Revenue Growth
- RARE 27.44
- AGO N/A
- 52 Week Low
- RARE $37.02
- AGO $72.57
- 52 Week High
- RARE $60.37
- AGO $96.60
- Technical
- Relative Strength Index (RSI)
- RARE 40.43
- AGO 60.88
- Support Level
- RARE $39.99
- AGO $85.16
- Resistance Level
- RARE $44.52
- AGO $91.64
- Average True Range (ATR)
- RARE 2.18
- AGO 1.43
- MACD
- RARE -0.03
- AGO 0.39
- Stochastic Oscillator
- RARE 17.75
- AGO 94.83
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About AGO Assured Guaranty Ltd.
Assured Guaranty Ltd. provides credit protection products to the United States and international public finance and structured finance markets, and manages assets across collateralized loan obligations as well as opportunity funds and liquid funds that build on its corporate credit, asset-based finance, municipal and healthcare experience. The company is operating in two segments Insurance segment and the Asset Management segment. The majority of the revenue earned by the company from the Insurance segment.